首页> 中文期刊> 《药学与临床研究》 >银杏二萜内酯葡胺注射液治疗急性脑梗死的临床疗效观察及对血Fib、CPR的影响

银杏二萜内酯葡胺注射液治疗急性脑梗死的临床疗效观察及对血Fib、CPR的影响

         

摘要

目的:探讨银杏二萜内酯葡胺注射液治疗轻中型脑梗死急性期的临床疗效及对患者血纤维蛋白原(Fib)、C反应蛋白(CRP)的影响.方法:选择88例临床确诊为轻中型急性脑梗死的患者,其中对照组44例采用急性脑梗死的常规治疗,试验组44例在对照组的基础上,加用银杏二萜内酯葡胺注射液静滴.观察治疗后的临床总有效率,采用NIHSS评分评估治疗前和治疗后7d、14d、30d、90d两组患者的神经功能障碍程度,治疗后14d、30d、90d使用日常生活能力量表中的Barthel指数来评估神经功能障碍康复程度,治疗前和治疗后90d时采用mRS进行综合生活能力评估,比较治疗前和治疗后14d Fib、CPR的结果.结果:治疗后的临床总有效率试验组明显高于对照组;试验组治疗后7d NIHSS评分较治疗前明显下降(P<0.05),两组治疗后14d、30d、90d评分较前均显著下降(P<0.05);治疗14d时试验组Barthel指数显著高于对照组(P<0.05);两组治疗后90d时mRS评分均明显低于治疗前(P<0.05);治疗后试验组的14d Fib、CPR数值较治疗前有明显下降(P<0.05).结论:银杏二萜内酯葡胺注射液可减少轻中型脑梗死患者的病情进展加重,改善神经功能缺损症状,降低血Fib、CPR.%Objective: To evaluate the efficacy and safety of ginkgo lactone meglumine injections in the treatment of mild to moderate acute cerebral infarction.Methods: Eighty hospitalized patients with acute cerebral infarction were collected,40 patients who received conventional basic therapy were served as the control group,while the other 40 patients in the experimental group received ginkgo lactone meglumine injections on the basis of the conventional therapy as those in the control group.The degrees of neurological deficit scored by the National Institutes of Health Stroke Scale(NIHSS)and the rehabilitation condition scored by Barthel index(BI)or modified Rankin Scale(mRS)were recorded for both the two groups before and 14 d,30 d and 90 d after treatment,respectively.And the levels of Fib and CRP of the two groups were measuredbefore treatment and 14 d after treatments.ResuIts: According to the NIHSS scores,the degrees of neurological deficit were significantly improved in the experimental group for a short term after 7 d and 14 d of treatment.The activities of daily living were significant enhanced in the experimental group after 14 d and 90 d of treatment when compared with the control group.After 14 d of treatments,the levels of Fib and CRP of the experimental group decreased significantly.ConcIusion:Ginkgo lactone meglumine injections probably improve the prognosis and reduce the disability of patients with acute cerebral infarction with lower levels of blood Fib and CRP.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号